Results 121 to 130 of about 56,599 (248)

Impact of methotrexate and etanercept drugs on serum levels of soluble toll-like receptor-2 in Iraqi patients with rheumatoid arthritis

Egyptian Rheumatology and Rehabilitation
Background Methotrexate and Etanercept are common treatment strategies for rheumatoid arthritis (RA) and are classified as conventional synthetic and biologic disease-modifying antirheumatic drugs respectively.
Muna R. Hameed, Faiq I. Gorial, Fayhaa M. khaleel   +2 more
doaj   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Comparison of efficacy of the tumour necrosis factor alpha blocking agents Etanercept and Infliximab in patients with active rheumatoid arthritis

, 2005
Background: Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA).
SANGARI D, DE FILIPPIS LG, MICALI G, ROMEO C, SCIBILIA G, BAGNATO, Gianfilippo, CALIRI A, LO GULLO R., BARTOLONE S   +8 more
core  

Mechanism and Efficacy of Etanercept in Treating Autoimmune-like Manifestations of Coronavirus Disease 2019 in elderly individuals

Immunobiology
During the COVID-19 pandemic, extensive research focused on universal treatments, but few studies addressed treatment regimens for elderly patients. This study aimed to evaluate the effects of etanercept, a TNF inhibitor, in elderly individuals with ...
Lizhong Zhang, Hongyi Li, Lei Shi, Jie Geng, Haojun Zhang, Haoran Chen, Peng Zhao, Yang Xiao, Jinqi Lu, Zhilun Li, Hongbin Pu, Chuandong Hou, Chenghui Li, Chumeng Gao, Xia Song, Zhuocheng Bao, Bing Zhai, Bo Guo, Bo Yang, Xuechun Lu, Qi Yu   +20 more
doaj   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study

, 2018
Naza Mohammed Ali Mahmood,1 Saad Abdulrahman Hussain,2 Raouf Rahim Mirza3 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Kurdistan Region, Iraq; 2Department of Pharmacology and Toxicology, Faculty of Pharmacy ...
Mahmood NMA, Mirza RR, Hussain SA
core  

Etanercept for the treatment of rheumatoid arthritis

, 2018
Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical trials in early as well as established disease.
Mysler, E, Zhao, S, Robert J Moots, Zhao, S; id_orcid, Sizheng Zhao, Eduardo Mysler, Moots, R J, Moots, RJ   +7 more
core   +1 more source

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data

BMC Rheumatology
Background Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments.
Marina G. Birck, Luck Lukusa, Denis Choquette, Gilles Boire, Walter P. Maksymowych, Harminder Singh, Waqqas Afif, Sasha Bernatsky   +7 more
doaj   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source